Recently, Mannan et al.1 reported that multi-gene panel testing provided increased sensitivity for detection of pathogenic mutations, which characterize hereditary breast and/or ovarian cancer syndromes.

I think it is important to recognize that while enormous progress has been made in our ability to identify germline mutations responsible for over 90% of hereditary breast cancer syndromes, patients who test negative (on multi-gene panel testing) should still be considered for the same screening and prophylactic treatments as those with similarly high pretest probabilities who test positive.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD